Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.67 |
| ▸ | CNR1 | P21554 | 3/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | HLCS | P50747 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758823 | 0.99 | CNR2 (0.64) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL30231847 | 0.96 | CNR2 (0.74) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL30231854 | 0.95 | CNR2 (0.71) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL12989865 | 0.92 | CNR2 (0.68) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL10140249 | 0.90 | CNR2 (0.66) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL12582940 | 0.90 | CNR2 (0.66) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL30165784 | 0.90 | CNR2 (0.66) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL19965709 | 0.86 | CNR2 (0.74) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL19965707 | 0.86 | CNR2 (0.74) | CNR2CNR1F2PRSS1PRSS2 | |
| SCHEMBL30341792 | 0.85 | CNR2 (0.67) | CNR2CNR1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20240100096-A1 | METHODS OF ACTIVATING T CELLS | ADOC SSF, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-4170031-A1 | APTAMERS AND USES THEREOF | Caris Science, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220401537-A1 | CHIMERIC RECEPTOR PROTEINS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-22 | — | — | US | disclosed |
| EP-4031583-A1 | CHIMERIC RECEPTOR PROTEINS AND USES THEREOF | Fred Hutchinson Cancer Center (US) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | CNR2 3696/4885CNR1 3075/4885F2 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.